IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated organ damage in several autoimmune diseases and recently it has been linked to pathogenesis of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative T cells. This could promote the autoimmune process by activation of immune cells \&stimulation of proliferation of B-cell and production of antibody

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interleukin23 in Systemic Lupus

NCT06713187

Systemic Lupus Erythematosus Related Interstial Lung Disease

RECRUITING NA

Haematological Indices in Systemic Lupus Erythematosus

NCT04110184

Rheumatic Diseases Systemic Lupus Erythematosus

UNKNOWN

Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These Patients

NCT06718283

Juvenile Systemic Lupus Erythematosus

RECRUITING

Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

NCT07017868

Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

RECRUITING

Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.

NCT06294483

Systemic Lupus Erythematosus

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases with SLE

110 patients with SLE will be divided to :

* 40 patients with lupus nephritis
* 40 patients interstitial lung disease
* 30 SLE patients without internal organ affection)

Serum level of IL-17

Intervention Type DIAGNOSTIC_TEST

Measurement of serum level of IL-17 :

1. To explore the role of IL-17 in systemic lupus erythematosus
2. To determine the relation between IL-17 and lupus disease activity
3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)

control group

30 sex and age matched healthy individuals as a control group

Serum level of IL-17

Intervention Type DIAGNOSTIC_TEST

Measurement of serum level of IL-17 :

1. To explore the role of IL-17 in systemic lupus erythematosus
2. To determine the relation between IL-17 and lupus disease activity
3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum level of IL-17

Measurement of serum level of IL-17 :

1. To explore the role of IL-17 in systemic lupus erythematosus
2. To determine the relation between IL-17 and lupus disease activity
3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE
* Age ≥ 18 years.
* Patients who are able and willing to give written informed consent